HEMA SWATHIRAJAN: Open Payments
NPI 1326138876 · DAVIE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$792 in 45 payments from 7 companies in 2025. Trend: 2023 $747 · 2024 $1,043 · 2025 $792
Food & beverage: $792
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $269 |
| Teva Pharmaceuticals USA, Inc. | 24 | $255 |
| Alkermes, Inc. | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
Products named: INGREZZA, AUSTEDO XR, UZEDY, ARISTADA, CAPLYTA, Auvelity, ABILIFY MAINTENA, ABILIFY ASIMTUFII.
Industry payments across FL — which companies pay providers there.
